HC Wainwright Cuts OnKure Therapeutics (NASDAQ:OKUR) Price Target to $27.00

OnKure Therapeutics (NASDAQ:OKUR) had its price objective cut by HC Wainwright from $34.00 to $27.00 in a report published on Monday morning,Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for OnKure Therapeutics’ Q1 2026 earnings at ($1.05) EPS, Q2 2026 earnings at ($0.93) EPS, Q3 2026 earnings at ($0.84) EPS, Q4 2026 earnings at ($0.88) EPS and FY2026 earnings at ($3.66) EPS.

Several other equities research analysts have also issued reports on OKUR. Wall Street Zen raised OnKure Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, March 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of OnKure Therapeutics in a research report on Monday, December 22nd. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $27.00.

OnKure Therapeutics Stock Performance

OnKure Therapeutics stock opened at $4.01 on Monday. OnKure Therapeutics has a fifty-two week low of $1.70 and a fifty-two week high of $5.28. The stock has a market cap of $54.34 million, a P/E ratio of -0.91 and a beta of 0.45. The firm’s fifty day moving average price is $2.91 and its 200-day moving average price is $2.89.

OnKure Therapeutics (NASDAQ:OKUR) last posted its quarterly earnings data on Monday, March 9th. The company reported ($0.99) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.15) by $0.16. On average, analysts predict that OnKure Therapeutics will post -4.05 earnings per share for the current year.

Hedge Funds Weigh In On OnKure Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in OKUR. XTX Topco Ltd purchased a new position in OnKure Therapeutics in the 4th quarter worth $52,000. ADAR1 Capital Management LLC purchased a new stake in OnKure Therapeutics during the fourth quarter valued at about $2,941,000. Kotler Kevin bought a new position in shares of OnKure Therapeutics during the fourth quarter valued at about $573,000. Barclays PLC grew its stake in shares of OnKure Therapeutics by 4,286.8% during the fourth quarter. Barclays PLC now owns 27,242 shares of the company’s stock valued at $79,000 after buying an additional 26,621 shares during the last quarter. Finally, Prosight Management LP increased its holdings in shares of OnKure Therapeutics by 204.9% in the fourth quarter. Prosight Management LP now owns 816,909 shares of the company’s stock worth $2,369,000 after buying an additional 548,950 shares during the period. Institutional investors own 90.98% of the company’s stock.

About OnKure Therapeutics

OnKure Therapeutics, Inc (NASDAQ: OKUR) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for oncology and autoimmune diseases. Headquartered in Westlake Village, California, OnKure is advancing small molecule drug candidates designed to modulate key signaling pathways implicated in cancer cell growth and immune system function.

The company’s lead oncology asset, OKI-179, is an orally available histone deacetylase (HDAC) inhibitor being evaluated in Phase I and Phase II clinical studies for a range of solid tumors.